Advances in prevention and treatment of radiation‐induced lymphopenia
Zhao Xuran, Sun Guangyi, Wang Shulian
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract:Currently, radiotherapy has been found to induce lymphopenia in multiple solid tumors, which has been proven to be associated with poor prognosis. Radiation‐induced lymphopenia (RIL) is associated with age, baseline lymphocyte count, tumor size and location and radiotherapy regimens (radiation fractionation, field size and technique), etc. In addition, several drugs and cytokines may help restore lymphocytes. Exploration of effective strategies to prevent or treat RIL may be an important future direction to improve prognosis of cancer patients.
Zhao Xuran,Sun Guangyi,Wang Shulian. Advances in prevention and treatment of radiation‐induced lymphopenia[J]. Chinese Journal of Radiation Oncology, 2022, 31(12): 1190-1193.
[1] Ellsworth SG.Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors[J]. Adv Radiat Oncol, 2018,3(4):512-519. DOI: 10.1016/j.adro.2018.08.014. [2] Koukourakis MI, Giatromanolaki A.Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy[J]. Crit Rev Oncol Hematol, 2021,159:103226. DOI: 10.1016/j.critrevonc.2021.103226. [3] Lee BM, Byun HK, Seong J.Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer[J]. Radiother Oncol, 2020,151:82-87. DOI: 10.1016/j.radonc.2020.07.026. [4] Deng W, Xu C, Liu A, et al.The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy[J]. Radiother Oncol, 2019,133:9-15. DOI: 10.1016/j.radonc.2018.12.002. [5] Shiraishi Y, Fang P, Xu C, et al.Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy[J]. Radiother Oncol, 2018,128(1):154-160. DOI: 10.1016/j.radonc.2017.11.028. [6] Xie X, Lin SH, Welsh JW, et al.Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes[J]. Radiother Oncol, 2021,154:187-193. DOI: 10.1016/j.radonc.2020.09.002. [7] Tang C, Liao Z, Gomez D, et al.Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2014,89(5):1084-1091. DOI: 10.1016/j.ijrobp.2014. 04.025. [8] Basler L, Andratschke N, Ehrbar S, et al.Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study[J]. Radiat Oncol, 2018,13(1):10. DOI: 10.1186/s13014-018-0952-y. [9] Yellu M, Fakhrejahani F, Ying J, et al. Lymphopenia as a predictor of survival in chemoradiation (CRT)‐treated stage III non‐small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2015,33(15_suppl): e18513‐e18513. [10] Yovino S, Kleinberg L, Grossman SA, et al.The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells[J]. Cancer Invest, 2013,31(2):140-144. DOI: 10.3109/07357907.2012. 762780. [11] MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation[J]. Cancer, 1978,41(1):108-111. DOI: 10.1002/1097-0142(197801)41:1<108::aid-cncr2820410116>3.0.co;2-z. [12] Saito T, Toya R, Matsuyama T, et al.Dosimetric predictors of treatment-related lymphopenia induced by palliative radiotherapy: predictive ability of dose-volume parameters based on body surface contour[J]. Radiol Oncol, 2017,51(2):228-234. DOI: 10.1515/raon-2016-0050. [13] Crocenzi T, Cottam B, Newell P, et al.A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma[J]. J Immunother Cancer, 2016,4:45. DOI: 10.1186/s40425-016- 0149-6. [14] Zhao Q, Chen G, Ye L, et al.Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC[J]. Radiat Oncol, 2019,14(1):86. DOI: 10.1186/s13014-019-1287-z. [15] Sun GY, Wang SL, Song YW, et al.Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2020,108(1):277-285. DOI: 10.1016/j.ijrobp.2020.02.633. [16] Yuan C, Wang Q.Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients[J]. Clin Transl Oncol, 2018,20(9):1219-1225. DOI: 10.1007/s12094-018-1851-2. [17] Wild AT, Herman JM, Dholakia AS, et al.Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2016,94(3):571-579. DOI: 10.1016/j.ijrobp.2015.11.026. [18] Sung W, Grassberger C, McNamara AL, et al. A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy[J]. Radiother Oncol, 2020,151:73-81. DOI: 10. 1016/j.radonc.2020.07.025. [19] Schad MD, Dutta SW, Muller DM, et al.Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer[J]. Adv Radiat Oncol, 2019,4(2):323-330. DOI: 10.1016/j.adro.2019.01.005. [20] Rudra S, Hui C, Rao YJ, et al.Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2018,101(1):217-225. DOI: 10.1016/j.ijrobp.2018. 01.069. [21] Kim N, Myoung Noh J, Lee W, et al.Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy[J]. Radiother Oncol, 2021,156:166-173. DOI: 10.1016/j.radonc.2020.12.019. [22] Sini C, Fiorino C, Perna L, et al.Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation[J]. Radiother Oncol, 2016,118(1):79-84. DOI: 10.1016/j.radonc.2015.11.020. [23] Newman NB, Sherry A, Anderson J, et al. Dose‐dependent association of vertebral body irradiation and lymphopenia during chemoradiation for esophageal cancer [J]. Int J Radiat Oncol Biol Phys, 2018,102(3):e37‐e38. DOI: 10.1016/j.ijrobp.2018.07.535. [24] Chadha AS, Liu G, Chen HC, et al.Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy?[J]. Int J Radiat Oncol Biol Phys, 2017,97(2):323-332. DOI: 10.1016/j.ijrobp.2016.10.046. [25] Liu J, Zhao Q, Deng W, et al.Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma[J]. Radiat Oncol, 2017,12(1):90. DOI: 10.1186/s13014-017-0824-x. [26] Saito T, Toya R, Yoshida N, et al.Spleen dose-volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer[J]. In Vivo, 2018,32(6):1519-1525. DOI: 10.21873/invivo.11409. [27] Jin JY, Mereniuk T, Yalamanchali A, et al.A framework for modeling radiation induced lymphopenia in radiotherapy[J]. Radiother Oncol, 2020,144:105-113. DOI: 10.1016/j.radonc.2019.11.014. [28] Xu C, Jin JY, Zhang M, et al.The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy[J]. Radiother Oncol, 2020,146:180-186. DOI: 10.1016/j.radonc.2020.02.015. [29] Liu KX, Ioakeim-Ioannidou M, Susko MS, et al.A multi-institutional comparative analysis of proton and photon therapy-induced hematologic toxicity in patients with medulloblastoma[J]. Int J Radiat Oncol Biol Phys, 2021,109(3):726-735. DOI: 10.1016/j.ijrobp.2020.09.049. [30] Mohan R, Liu AY, Brown PD, et al.Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons[J]. Neuro Oncol, 2021,23(2):284-294. DOI: 10.1093/neuonc/noaa182. [31] Saavedra MM, Henríquez-Hernández LA, Lara PC, et al.Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients[J]. J Radiat Res, 2010,51(5):603-607. DOI: 10.1269/jrr.10030. [32] Koukourakis MI, Ktenidou-Kartali S, Bourikas G, et al.Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients[J]. Cancer Immunol Immunother, 2003,52(2):127-131. DOI: 10.1007/s00262-002- 0342-y. [33] Koukourakis GV, Baksevanis CN, Zambatis H, et al.Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer[J]. Int J Radiat Biol, 2009,85(1):96-104. DOI: 10.1080/09553000802635070. [34] Perales MA, Goldberg JD, Yuan J, et al.Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation[J]. Blood, 2012,120(24):4882-4891. DOI: 10.1182/blood-2012-06-437236. [35] Trédan O, Ménétrier-Caux C, Ray-Coquard I, et al.ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients[J]. Ann Oncol, 2015,26(7):1353-1362. DOI: 10.1093/annonc/mdv173. [36] Byun HK, Kim KJ, Han SC, et al.Effect of interleukin-7 on radiation-induced lymphopenia and its antitumor effects in a mouse model[J]. Int J Radiat Oncol Biol Phys, 2021,109(5):1559-1569. DOI: 10.1016/j.ijrobp.2020.12.004. [37] Kim JH, Kim YM, Choi D, et al.Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy[J]. Clin Transl Immunology, 2020,9(9):e1168. DOI: 10.1002/cti2.1168. [38] Abrams D, Lévy Y, Losso MH, et al.Interleukin-2 therapy in patients with HIV infection[J]. N Engl J Med, 2009,361(16):1548-1559. DOI: 10.1056/NEJMoa0903175. [39] Ahmadzadeh M, Rosenberg SA.IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients[J]. Blood, 2006,107(6):2409-2414. DOI: 10.1182/blood-2005- 06-2399. [40] Conlon KC, Lugli E, Welles HC, et al.Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer[J]. J Clin Oncol, 2015,33(1):74-82. DOI: 10.1200/JCO.2014.57.3329.